Lumbar Laminectomy
L3-S1 Interbody Fusion and Posterior Spinal Segmental Fusion

David A. Lundin, MD
Neurosurgeon
Pomona Valley Hospital
Pomona, CA

The information provided herein is provided for educational purposes and represents the surgical techniques used by Dr. Lundin. Catheter placement is intended for guidance only and is subject to the individual expertise, experience and school-of-thought of the surgeon placing the catheter. Always refer to the drug manufacturer’s prescribing information when administering any drug with the ON-Q* Pain Relief System. This protocol is not to be construed as a specific recommendation of I-Flow*, LLC.

SAMPLE PROTOCOL

Pump Used: PM028-A: 400 ml x 4 ml/hr (dual; 2 ml/site)
(2) 5 inch ON-Q* SilverSoaker* catheters

Tunneler Used: ACC08: 17 GA x 8 inch reusable tunneler
ACC08S: 17 GA x 8 inch tunneler sheath

Drugs in Pump: Local anesthetic of physician’s choice.

Pre-incision infiltration: Local anesthetic into skin and subcutaneous tissue.

Catheter Placement: Stab incision. After fascial closure, tunnel each catheter under the fascia, above the muscle through the length of incision.

Postoperative Bolus Technique: A bolus dose of local anesthetic may be administered with consideration given to total daily dose and patient’s clinical status.

Catheter Securement Technique: Steri-Strips™ and Tegaderm™ above wound dressing.

Results with ON-Q*:

<table>
<thead>
<tr>
<th></th>
<th>Before ON-Q*</th>
<th>After ON-Q*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pain Management Method</td>
<td>PCA morphine</td>
<td>PCA</td>
</tr>
<tr>
<td>Average Narcotic Usage</td>
<td>2 days PCA with supplemental oral pain meds</td>
<td>1 day PCA. Decrease in oral pain meds</td>
</tr>
<tr>
<td>Average Length of Stay</td>
<td>5 days</td>
<td>3-4 days</td>
</tr>
</tbody>
</table>

(Continued on Page 2)

CAUTIONS

• Patient may experience loss of motor control or feeling at and around the surgical area. Physician should instruct patient on appropriate measures to follow to avoid patient injury.

• Medications used with this system should be administered in accordance with instructions provided by the drug manufacturer. Surgeon is responsible for prescribing drug based on each patient’s clinical status (e.g., age, body weight, disease state of patient, concomitant medication(s)).

• Vasoconstrictors such as epinephrine or adrenaline are not recommended for continuous infusions.

• Refer to ON-Q* Pump Directions for Use for full instructions on using the ON-Q* Pain Relief System.

ON-Q*
PAIN RELIEF SYSTEM
These images are for general guidance only and not to be interpreted as precise anatomical illustration or construed as a specific recommendation of I-Flow* LLC.

**Other notes:** Increase in patient mobility on post-operative day one.

**Warning:** Caution should be used to prevent inadvertent epidural or spinal administration of the local anesthetic. Educate the patient and caregivers on the signs and symptoms of an intraspinal infusion such as lower extremity motor weakness and stop the infusion if necessary.

1. **Puncture, stab incision made superior to closed fascia**

2. **Tunneling**
3. Placement of first catheter, second catheter tunneling

4. Securement
**INDICATIONS FOR USE**

- The ON-Q* pump is intended to provide continuous and/or intermittent delivery of medication (such as local anesthetics or narcotics) to or around surgical wound sites and/or close proximity to nerves for preoperative, perioperative and postoperative regional anesthesia and/or pain management. Routes of administration include: intraoperative site, perineural, percutaneous, and epidural.

- ON-Q* is intended to significantly decrease pain and narcotic use when used to deliver local anesthetics to or around surgical wound sites, or close proximity to nerves, when compared to narcotic only pain management.

**CONTRAINDICATIONS**

- ON-Q* is not intended for blood, blood products, lipids, fat emulsions, or Total Parenteral Nutrition (TPN).

- ON-Q* is not intended for intravascular delivery.

---

There are inherent risks in all medical devices. Please refer to the product labeling for **Indications**, **Cautions**, **Warnings**, and **Contraindications**. Failure to follow the product labeling could directly impact patient safety. Physician is responsible for prescribing and administering medications per instructions provided by the drug manufacturer. Refer to www.iflo.com for product safety Technical Bulletins.

*Registered Trademark or Trademark of Kimberly-Clark Worldwide, Inc. © 2013 KCWW. All rights reserved.

Steri-Strip and Tegaderm are trademarks of 3M Healthcare.

MK-00475 07/2013